Related Experiment Video
Updated: Jul 10, 2026
15:12
Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
Published on: May 10, 2014
Toward cystic fibrosis gene therapy
1Department of Molecular Pharmacology, Stanford University, School of Medicine, California 94305-5332, USA.
Annual Review of Medicine
|January 1, 1997
Summary
Gene therapy for cystic fibrosis (CF) aims to correct defective chloride transport. While promising vectors like adenovirus and AAV show potential, immune response and efficiency remain challenges for clinical success.
Area of Science:
- Genetics
- Pulmonology
- Biotechnology
Background:
- Cystic fibrosis (CF) is a prevalent genetic disorder impacting epithelial chloride transport and causing progressive lung disease.
- Despite treatment advancements, CF remains a lethal condition, frequently resulting in early adulthood mortality.
- CF research serves as a crucial model for gene therapy development in other genetic diseases.
Purpose of the Study:
- To review the progress and challenges in developing gene therapy for cystic fibrosis.
- To highlight the role of CF as a model for gene therapy research.
- To discuss the potential of gene therapy to address the underlying defect in CF.
Main Methods:
- Review of preclinical and clinical research on gene therapy vectors for CF.
- Analysis of vector types including adenovirus, adeno-associated virus, and liposomes.
- Identification of host immune response and vector efficiency as key research areas.
Main Results:
- Development of various vectors (adenovirus, AAV, liposomes) for CF gene therapy.
- Clinical studies indicate that host immune response and low vector efficiency impede therapeutic success.
- Significant research efforts are focused on overcoming these barriers.
Conclusions:
- Gene therapy holds promise for treating cystic fibrosis by correcting the fundamental genetic defect.
- Refining vector technology is essential to overcome immune responses and improve efficiency.
- Continued research aims to translate CF gene therapy from the laboratory to clinical application.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...